PROSTAT SPESİFİK ANTİJEN 2.5-4 NG/ML ARALIĞINDA PSAD VE PROSTAT BİYOPSİ SONUÇLARININ DEĞERLENDİRİLMESİ Evaluation of PSAD and Prostate Biopsy Results in Prostat Specific Antigen Between 2.5-4 ng/mL
ÖZETAmaç: Bu çalışmanın amacı; PSA 2.5- 4 ng/ml arasında olan hastaların verilerini ve bu aralıktakanser saptama oranını değerlendirmektir.Gereç ve Yöntemler: Ocak 2011-Aralık 2014 tarihleri arasında hastanemizde Prostat Kanseri(PCa) şüphesi olan ve total PSA değeri 2.5-4 ng/ml olan 83 hastadan alınan prostat biyopsisonuçları retrospektif olarak değerlendirildi. PSA yüksekliği ve/veya anormal rektal muayenebulgusu ile kliniğimize başvuran her hastaya transrektal ultrason eşliğinde prostat biyopsisi uygulandı.Hastaların yaşları, total PSA değerleri, PSAD, prostat volümleri, parmakla rektal muayenelerive prostat biyopsisi sonuçları retrospektif olarak değerlendirildi.Sonuç: Hastaların ortalama yaşı 64.1±8.3 (43-78) idi. 0rtalama PSA degerleri 3.1±0.8 ng/mlidi. 16 hastada prostat kanseri saptandı. 67 hastada benign patolojiler saptandı. Prostat kanserisaptanan hastaların yaşları, PSA, PSAD, prostat volümleri sırası ile; 63.1±9.4. 3.34±0.37.0.06±0.01, 50.1±9.6 idi. Prostat kanseri saptanmayan grupta ise bu değerler; 64.4±8.6,3.23±0.4, 0.05±0.01, 66.1±17.7 idi. Yalnızca prostat boyutu; prostat kanseri saptanan hastalardaanlamlı olarak küçük saptandı. 22 hastada anormal rektal muayene bulgusu saptandı.16 (%19.2) hastada prostat kanseri saptandı. Hastaların ortalama gleason skoru 6.5 (6-8) idi.Tartışma: PSA 2.5-4 ng/ml aralığında kanser saptama oranımız literatürle uyumlu bulunmuştur.Bu hastaların klinik olarak tedavi edilmesi gerektiğini düşünmekteyiz. Bu nedenle 2.5 ng/mlPSA seviyesinde hastalara prostat biyopsisi yapılması gerektiği düşüncesindeyiz.Anahtar Sözcükler: Prostat spesifik antijen 2.5-4ng/ml; Prostat kanseri; Prostat biyopsisiABSTRACTObjective: The aim of this study; we retrospective analyzed data of the results of prostatebiopsy of patients who had the prostate specific antigen (PSA) levels between 2.5- 4 ng/ml andwe evaluate to the cancer detection rate in this range.Material and Methods: Between January 2011 and December 2014, prostate biopsy resultsfrom 83 patients with a total PSA level of 2.5-4 ng / mL, which were suspected to be PCA inour hospital, were evaluated retrospectively.Each patient underwent transrectal ultrasoundguided prostate biopsy. The age, total PSA, prostate volume, digital rectal examination andpathology result were evaluated for each patient.Results: The mean age of the patients was 64.1 ± 8.3 (43-78). Mean PSA values were 3.1 ±0.8 ng/ml. Prostate cancer was detected in 16 patients. Benign pathologies were detectedin 67 patients. Patients with prostate cancer is detected; Ages, PSA, PSAD, prostate volumes;63.1 ± 9.4, 3.34 ± 0.37, 0.06 ± 0.01, 50.1 ± 9.6, respectively. In the group without prostatecancer, these values were; 64.4 ± 8.6, 3.23 ± 0.4, 0.05 ± 0.01, 66.1 ± 17.7, respectively. Onlysmall prostate size was found significant in prostate cancer patients.Abnormal digital rectalexamination was found in 22(%26) patients .Prostate cancer was detected in 16 (19.2%)patients. Gleason score of Prostate cancer patients were 6.5 (6-8).Conclusion: Our cancer detection rate in PSA range 2.5-4 ng / ml was found to be consistentwith the literature. We think that these cancers should also be treated clinically. For this reasonwe suggest to do prostate biopsy for patients who have PSA level over 2.5 ng / ml.Keywords: Prostate-specific antigen 2.5-4ng/ml; Prostate cancer; Prostate biopsy
___
- Printz C. Many unknowns in low-risk prostate cancer treatment.
Ongoing studies and biomarker research may shed light on best
approach. Cancer. 2009;115:4645-6.
2. Wang MC, Valenzuala LA, Murphy GP, Chu TM: Purification of a
human prostate specific antigen. Invest Urol. 1979;17: 159.
3. Lilja II: A kallikrein like serin protease in prostatic fluid cleaves the
predominant seminal vesicle protein. J Clin İnvest. 1985;76: 1899.
4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E:
Prostate specific antigen as a serum marker for adenocarcinoma of
the prostate. N Eng J Med. 1987;317: 909.
5. Brawer MK: Laboratory studies for the detection of carcinoma of
prostate. Urol Clin North Am. 1990;17: 759-67.
6. Stamey TA: PSA in the diagnosis and treatment of
adenocarcinoma of the prostate. Monogr Urol. 1989;10: 49-50.
7. Ng TK, Vasilareas D, Mitterdorfer AJ, Maher PO, Lalak A. Prostate
cancer detection with digital rectal examination, prostate-specific
antigen, transrectal ultrasonography and biopsy in clinical urological
practice. BJU Int. 2005;95:545-8.
8. National Collaborating Centre for Cancer. Prostate cancer